LAVA Therapeutics N.V. (LVTX) Bundle
A Brief History of LAVA Therapeutics N.V. (LVTX)
Company Overview
LAVA Therapeutics N.V. is a biotechnology company headquartered in Utrecht, Netherlands. The company focuses on developing novel T-cell engaging bispecific antibody therapies for cancer treatment.
Financial Performance
| Fiscal Year | Revenue | Net Loss | Cash Position |
|---|---|---|---|
| 2023 | $0.4 million | $44.3 million | $81.3 million |
Stock Performance
LVTX trades on the Nasdaq Global Market with the following key metrics:
- IPO Date: February 4, 2021
- IPO Price: $16 per share
- Market Capitalization: Approximately $80 million (as of January 2024)
Clinical Pipeline
Current clinical-stage programs include:
- LAVA-051: Phase 1/2 trial for multiple myeloma
- LAVA-1207: Preclinical stage gamma delta T-cell therapy
Key Partnerships
Collaboration with Janssen Biotech for gamma delta T-cell platform technology, with potential milestone payments up to $1.2 billion.
Research and Development
| R&D Expenditure | 2023 Amount |
|---|---|
| Total R&D Expenses | $37.2 million |
Leadership
CEO: Ivar Mathisen
Corporate Milestones
- Nasdaq listing in February 2021
- Raised $207 million in public offering
- Initiated Phase 1/2 trial for LAVA-051 in 2022
A Who Owns LAVA Therapeutics N.V. (LVTX)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Versant Ventures | 4,238,095 | 19.9% |
| Fidelity Management & Research | 1,752,433 | 8.2% |
| Orbimed Advisors LLC | 1,625,000 | 7.6% |
Key Ownership Details
LAVA Therapeutics N.V. (LVTX) ownership structure as of Q4 2023 includes:
- Public Float: 21,300,000 shares
- Institutional Ownership: 68.3%
- Insider Ownership: 12.7%
Top Institutional Investors
| Investor | Total Investment | Investment Date |
|---|---|---|
| Versant Ventures | $45.2 million | February 2022 |
| OrbiMed Advisors | $38.7 million | September 2021 |
Management Ownership
Executive leadership shareholding includes:
- CEO Hans Schikan: 425,000 shares
- CFO Rob de Ree: 185,000 shares
- Chief Scientific Officer: 210,000 shares
LAVA Therapeutics N.V. (LVTX) Mission Statement
Company Overview
LAVA Therapeutics N.V. is a clinical-stage biotechnology company focused on developing novel T cell engaging immunotherapies for cancer treatment.
Strategic Focus Areas
- Developing gamma-delta T cell engager therapeutics
- Targeting hematological and solid tumors
- Advancing precision immunotherapy platforms
Financial Metrics
| Metric | Value |
|---|---|
| Market Capitalization | $76.4 million (as of January 2024) |
| Cash and Cash Equivalents | $56.2 million (Q3 2023) |
| Research and Development Expenses | $23.1 million (2023) |
Pipeline Development
LAVA-051 is the lead therapeutic candidate targeting solid tumors and hematological malignancies.
Key Research Objectives
- Advancing gamma-delta T cell engager technology
- Developing precision cancer immunotherapies
- Expanding therapeutic applications across multiple cancer types
Clinical Trial Status
| Program | Phase | Indication |
|---|---|---|
| LAVA-051 | Phase 1/2 | Multiple Myeloma |
Corporate Structure
Publicly traded on NASDAQ under ticker symbol LVTX, headquartered in Utrecht, Netherlands.
How LAVA Therapeutics N.V. (LVTX) Works
Company Overview
LAVA Therapeutics N.V. is a clinical-stage biotechnology company focused on developing novel T cell engaging therapeutics for cancer treatment. The company was founded in 2012 and is headquartered in Utrecht, Netherlands.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Market Capitalization | $52.3 million |
| Cash and Cash Equivalents | $37.6 million |
| Net Loss | $44.2 million |
| Research and Development Expenses | $32.5 million |
Key Product Pipeline
- LAVA-051: Gamma delta T cell engager for solid tumors
- LAVA-1207: Bispecific T cell engager for solid tumors
- LAVA-1044: Preclinical stage cancer therapeutic
Clinical Development Status
LAVA Therapeutics is currently conducting Phase 1/2 clinical trials for its lead product candidates, with a focus on innovative T cell engaging therapies.
Technology Platform
- Proprietary gamma delta T cell engaging platform
- Bispecific T cell engager (BiTE) technology
- Precision targeting of cancer cells
Operational Metrics
| Metric | 2023 Data |
|---|---|
| Number of Employees | 68 |
| Active Clinical Trials | 3 |
| Research Collaborations | 2 |
Stock Performance
NASDAQ ticker LVTX traded at $1.24 per share as of January 2024, with a 52-week range between $0.72 and $2.45.
How LAVA Therapeutics N.V. (LVTX) Makes Money
Revenue Streams
LAVA Therapeutics generates revenue through the following primary mechanisms:
- Research and development collaborations
- Potential licensing agreements
- Grant funding
- Equity financing
Financial Performance
| Financial Metric | 2023 Amount (USD) |
|---|---|
| Total Revenue | $4.2 million |
| Research Grants | $2.1 million |
| Collaboration Income | $1.5 million |
| Net Loss | $37.6 million |
Key Product Development
LAVA focuses on developing gamma delta T cell therapeutics targeting various cancers, which represent potential future monetization opportunities.
Strategic Partnerships
- Merck collaboration for bispecific gamma delta T cell engagers
- Research agreements with pharmaceutical research institutions
Funding Sources
| Funding Type | Amount Raised (2023) |
|---|---|
| Public Offering | $35.4 million |
| Private Placement | $12.6 million |
LAVA Therapeutics N.V. (LVTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.